Kidney Fibrosis - Pipeline Review, H1 2018

  • ID: 4521325
  • Drug Pipelines
  • 134 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AdAlta Ltd
  • BiOrion Technologies BV
  • Epigen Biosciences Inc
  • Galectin Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Redx Pharma Plc
  • MORE
Kidney Fibrosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H1 2018, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights:

This latest pipeline guide Kidney Fibrosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 27 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AdAlta Ltd
  • BiOrion Technologies BV
  • Epigen Biosciences Inc
  • Galectin Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Redx Pharma Plc
  • MORE
Introduction

Report Coverage

Kidney Fibrosis - Overview

Kidney Fibrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Kidney Fibrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kidney Fibrosis - Companies Involved in Therapeutics Development

AdAlta Ltd

Angion Biomedica Corp

BiOrion Technologies BV

Cellmid Ltd

Epigen Biosciences Inc

Evotec AG

Galectin Therapeutics Inc

Genzyme Corp

Isarna Therapeutics GmbH

Les Laboratoires Servier SAS

Pharmaxis Ltd

ProMetic Life Sciences Inc

Redx Pharma Plc

Regulus Therapeutics Inc

Sirnaomics Inc

Symic Biomedical Inc

Vascular Biogenics Ltd

Kidney Fibrosis - Drug Profiles

1D-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AD-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3586 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-4201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMP-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOT-191 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAB-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Tissue Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluorofenidone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-0047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Inhibit MIR199a for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAT-1251 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAT-505 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-4820 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5033A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5338K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5382A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REDX-06109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Insulin-Regulated AminoPeptidase for Alzheimer’s Disease, Cardiac and Renal Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin for Kidney Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEW-7197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-0004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-4P5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Wnt-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kidney Fibrosis - Dormant Projects

Kidney Fibrosis - Discontinued Products

Kidney Fibrosis - Product Development Milestones

Featured News & Press Releases

Nov 13, 2017: AdAlta to present at Anti-Fibrotic Drug Development Summit in Boston

Sep 06, 2017: Pharmaxis Announces Anti Fibrotic LOXL2 Program Clears Preclinical Development And Set To Commence Phase 1 Trials

Sep 04, 2017: AdAlta to present kidney fibrosis data at Australian and New Zealand Society of Nephrology Annual Scientific Meeting

Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-

Nov 18, 2016: ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting

Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis

Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics

Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting

Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe

Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2

Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter

Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Kidney Fibrosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Kidney Fibrosis - Pipeline by AdAlta Ltd, H1 2018

Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H1 2018

Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H1 2018

Kidney Fibrosis - Pipeline by Cellmid Ltd, H1 2018

Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H1 2018

Kidney Fibrosis - Pipeline by Evotec AG, H1 2018

Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2018

Kidney Fibrosis - Pipeline by Genzyme Corp, H1 2018

Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2018

Kidney Fibrosis - Pipeline by Les Laboratoires Servier SAS, H1 2018

Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H1 2018

Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2018

Kidney Fibrosis - Pipeline by Redx Pharma Plc, H1 2018

Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc, H1 2018

Kidney Fibrosis - Pipeline by Sirnaomics Inc, H1 2018

Kidney Fibrosis - Pipeline by Symic Biomedical Inc, H1 2018

Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H1 2018

Kidney Fibrosis - Dormant Projects, H1 2018

Kidney Fibrosis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Kidney Fibrosis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Kidney Fibrosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AdAlta Ltd
  • Angion Biomedica Corp
  • BiOrion Technologies BV
  • Cellmid Ltd
  • Epigen Biosciences Inc
  • Evotec AG
  • Galectin Therapeutics Inc
  • Genzyme Corp
  • Isarna Therapeutics GmbH
  • Les Laboratoires Servier SAS
  • Pharmaxis Ltd
  • ProMetic Life Sciences Inc
  • Redx Pharma Plc
  • Regulus Therapeutics Inc
  • Sirnaomics Inc
  • Symic Biomedical Inc
  • Vascular Biogenics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll